pimobendan has been researched along with Mitral Valve Insufficiency in 14 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Mitral Valve Insufficiency: Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated." | 9.22 | Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016) |
| "To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)." | 9.11 | Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005) |
| "The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)." | 7.85 | Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017) |
| "Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated." | 5.22 | Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016) |
| "To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)." | 5.11 | Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005) |
| "For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day." | 3.88 | Clinical findings and survival time in dogs with advanced heart failure. ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018) |
| "The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)." | 3.85 | Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017) |
| "This retrospective study reports the survival time [onset of congestive heart failure (CHF) to death from any cause] of 21 dogs with mitral regurgitation (MR) and CHF treated with a combination of furosemide, angiotensin-converting enzyme inhibitor (ACEI, benazepril, or enalapril), pimobendan, spironolactone, and amlodipine." | 3.77 | Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. ( de Madron, E; King, JN; Strehlau, G; White, RV, 2011) |
| "Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs." | 2.46 | Current use of pimobendan in canine patients with heart disease. ( Boswood, A, 2010) |
| "Pimobendan (0." | 1.91 | Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation. ( Boonpala, P; Ji-Au, W; Kijtawornrat, A; Kumphune, S; Panyasing, Y; Saengklub, N; Srikam, S, 2023) |
| "cardiac death or death for other causes)." | 1.62 | Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols. ( Bagardi, M; Brambilla, PG; Galizzi, A; Locatelli, C; Malchiodi, D; Zanaboni, A, 2021) |
| "Pimobendan has a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting PDEIII." | 1.34 | Effects of pimobendan for mitral valve regurgitation in dogs. ( Hara, A; Kanno, N; Kano, R; Kawasaki, M; Kuse, H; Sasaki, Y, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Boonpala, P | 1 |
| Saengklub, N | 1 |
| Srikam, S | 1 |
| Ji-Au, W | 1 |
| Panyasing, Y | 1 |
| Kumphune, S | 1 |
| Kijtawornrat, A | 1 |
| Bagardi, M | 1 |
| Locatelli, C | 1 |
| Zanaboni, A | 1 |
| Galizzi, A | 1 |
| Malchiodi, D | 1 |
| Brambilla, PG | 1 |
| Beaumier, A | 1 |
| Rush, JE | 1 |
| Yang, VK | 1 |
| Freeman, LM | 1 |
| Hezzell, MJ | 1 |
| Block, CL | 1 |
| Laughlin, DS | 1 |
| Oyama, MA | 2 |
| Mizuno, M | 1 |
| Yamano, S | 1 |
| Chimura, S | 1 |
| Hirakawa, A | 1 |
| Takusagawa, Y | 1 |
| Sawada, T | 1 |
| Maetani, S | 1 |
| Takahashi, A | 1 |
| Mizuno, T | 1 |
| Harada, K | 1 |
| Shinoda, A | 1 |
| Uchida, S | 1 |
| Takeuchi, J | 1 |
| Mizukoshi, T | 1 |
| Endo, M | 1 |
| Uechi, M | 2 |
| Boswood, A | 3 |
| Häggström, J | 1 |
| Gordon, SG | 1 |
| Wess, G | 1 |
| Stepien, RL | 1 |
| Keene, BW | 1 |
| Bonagura, J | 1 |
| MacDonald, KA | 1 |
| Patteson, M | 2 |
| Smith, S | 2 |
| Fox, PR | 1 |
| Sanderson, K | 1 |
| Woolley, R | 1 |
| Szatmári, V | 1 |
| Menaut, P | 1 |
| Church, WM | 1 |
| O'Sullivan, ML | 1 |
| Jaudon, JP | 1 |
| Kresken, JG | 1 |
| Rush, J | 1 |
| Barrett, KA | 1 |
| Rosenthal, SL | 1 |
| Saunders, AB | 1 |
| Ljungvall, I | 1 |
| Deinert, M | 1 |
| Bomassi, E | 1 |
| Estrada, AH | 1 |
| Fernandez Del Palacio, MJ | 1 |
| Moise, NS | 1 |
| Abbott, JA | 1 |
| Fujii, Y | 1 |
| Spier, A | 1 |
| Luethy, MW | 1 |
| Santilli, RA | 1 |
| Tidholm, A | 1 |
| Watson, P | 1 |
| de Madron, E | 1 |
| King, JN | 1 |
| Strehlau, G | 1 |
| White, RV | 1 |
| Tissier, R | 1 |
| Chetboul, V | 1 |
| Moraillon, R | 1 |
| Nicolle, A | 1 |
| Carlos, C | 1 |
| Enriquez, B | 1 |
| Pouchelon, JL | 1 |
| Smith, PJ | 1 |
| French, AT | 1 |
| Van Israël, N | 1 |
| Smith, SG | 1 |
| Swift, ST | 1 |
| Lee, AJ | 1 |
| Corcoran, BM | 1 |
| Dukes-McEwan, J | 1 |
| Kanno, N | 1 |
| Kuse, H | 1 |
| Kawasaki, M | 1 |
| Hara, A | 1 |
| Kano, R | 1 |
| Sasaki, Y | 1 |
1 review available for pimobendan and Mitral Valve Insufficiency
| Article | Year |
|---|---|
Current use of pimobendan in canine patients with heart disease.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Diseases; Ma | 2010 |
3 trials available for pimobendan and Mitral Valve Insufficiency
| Article | Year |
|---|---|
Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs | 2018 |
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral V | 2016 |
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Electrocardiography; Heart Failure; Mitral Valve; M | 2005 |
10 other studies available for pimobendan and Mitral Valve Insufficiency
| Article | Year |
|---|---|
Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation.
Topics: Animals; Dog Diseases; Dogs; Hydrogen Peroxide; Mitochondria; Mitral Valve Insufficiency; Muscle Cel | 2023 |
Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cohort Studies; Death; Dog Diseases; Dogs; Female | 2021 |
Clinical trial results extend drug licence.
Topics: Animals; Clinical Trials as Topic; Dog Diseases; Dogs; Legislation, Drug; Mitral Valve Insufficiency | 2017 |
Clinical findings and survival time in dogs with advanced heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val | 2018 |
What Is Your Diagnosis?
Topics: Animals; Atherosclerosis; Bird Diseases; Cardiotonic Agents; Diagnosis, Differential; Diuretics; Ech | 2018 |
Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral Valve Insuffici | 2017 |
Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Clinical Trials as Topic; Dog Diseases; Dogs; Mitral Valv | 2011 |
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Death, Sudden, | 2011 |
Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy.
Topics: Animals; Dogs; Echocardiography; Female; Hypertrophy, Left Ventricular; Male; Mitral Valve Insuffici | 2005 |
Effects of pimobendan for mitral valve regurgitation in dogs.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiotonic Agents; Catecholamines; | 2007 |